MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$27,052
Unit: Dollar
Positive Cash Flow Breakdown
    • Proceeds from sale of common sto...
    • Expenses allocated by sanovas on...
    • Stock-based compensation expense
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Advances from related parties, n...
    • Increase in accounts payable and...
    • Decrease in lease liability
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss
-307,397
-590,489
-623,127
-568,791
Stock-based compensation expense
24,782
210,016
281,246
277,226
Depreciation expense
-
-
0
0
Amortization of right of use asset
-
-
-
640
Amortization of rou asset
642
642
2,563
-
Expenses allocated by sanovas on behalf of company
165,375
165,375
165,375
165,375
Increase in accounts payable and accrued liabilities
-20,559
104,757
47,131
20,947
Decrease in lease liability
-474
-474
-446
-194
Increase in accrued interest
960
960
960
960
Total adjustments
170,726
481,276
494,908
464,954
Net cash (used in) operating activities
-136,671
-109,213
-128,219
-103,837
Proceeds from collection of stock subscription receivable
0
125,000
0
0
Proceeds from sale of common stock
200,000
-
212,000
100,000
Advances from related parties, net
-36,277
-30,381
-69,099
88,163
Net cash provided by financing activities
163,723
94,619
142,901
103,090
Net (decrease) in cash
27,052
-14,594
14,682
-747
Cash at beginning of period
180
14,774
92
6,060
Cash at end of period
27,232
180
14,774
92
Unit: Dollar. Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from sale ofcommon stock$200,000 (132.56%↑ Y/Y)Net cash provided byfinancing activities$163,723 (-49.01%↓ Y/Y)Canceled cashflow$36,277 Expenses allocated bysanovas on behalf of...$165,375 (-50.00%↓ Y/Y)Stock-based compensationexpense$24,782 (-94.86%↓ Y/Y)Increase in accruedinterest$960 (-50.00%↓ Y/Y)Amortization of rou asset$642 Net (decrease) incash$27,052 (618.14%↑ Y/Y)Canceled cashflow$136,671 Advances from relatedparties, net-$36,277 (-142.64%↓ Y/Y)Total adjustments$170,726 (-81.25%↓ Y/Y)Canceled cashflow$21,033 Net cash (used in)operating activities-$136,671 (58.11%↑ Y/Y)Canceled cashflow$170,726 Increase in accountspayable and accrued...-$20,559 (-121.73%↓ Y/Y)Decrease in leaseliability-$474 (-36.21%↓ Y/Y)Net loss-$307,397 (75.14%↑ Y/Y)

RetinalGenix Technologies Inc. (RTGN)

RetinalGenix Technologies Inc. (RTGN)